Highest-materiality recent filing
Panacea Life Sciences Holdings files N7 Enterprises financials showing losses and going concern
N7 had $326k revenue and $82k net loss in 2022; 6mo2023 revenue $1.18M, net loss $147k.
Panacea Life Sciences acquires 8 Nitro Kava retail stores for 78,530 Series N-7 Preferred shares
Acquired 8 Nitro Kava retail stores and a distribution center in Tampa, FL from N7 Enterprises sellers.
Panacea Life Sciences acquires PUR Life Medical franchise for $1M cash plus up to $1.6M contingent
Purchase price of $1M cash plus up to $1.6M payable over 4 years based on franchise fee and royalty collection.
Panacea Life Sciences to acquire eight Nitro Kava stores in Tampa for convertible preferred shares
Acquisition of 8 retail locations, distribution facilities, warehouse in Tampa area for 84,548 Series E convertible preferred shares.
Panacea Life Sciences agrees to repay $385K convertible note via cash and equity conversion
Company to pay $135,000 funded under CEO line of credit on Feb 13, 2023; $100,000 by June 30, 2023.
Panacea Life Sciences signs LOI to acquire N7 Enterprises for 22.2M shares
Panacea will issue 22.2 million common shares to N7 Enterprises stockholders.
Panacea exchanges 350 Series A shares for $385K convertible note & warrants
Issued $385K 10% OID senior convertible note due March 2023, convertible at $1.40/sh.
Board concluded Q3 2021 unaudited financials filed Nov 22 should no longer be relied upon due to errors in revenue, cost of goods sold, lease liability, options and warrants.
Panacea Life Sciences 2020 revenue $9.0M, net loss $5.2M; auditor raises going concern
Revenue $9.0M in 2020 vs $2.2M in 2019; net loss $5.2M vs $2.8M.
Panacea Life Sciences closes $1M private placement on Nov 30, 2021
Closed private placement previously announced on Nov 24, 2021; received $1,000,000 wire.
Panacea Life Sciences secures $1M via convertible note and warrant sale to Lincoln Park Capital
Sold $1.1M senior convertible note (net $1M) and warrants for 785,715 shares at $1.40 to Lincoln Park Capital Fund.
Company changed name to Panacea Life Sciences Holdings, Inc., effective Oct 25, 2021.
Exactus restates Q2 2021 financials; related-party revenue of $4.7M improperly recognized
Board concluded Q2 2021 Form 10-Q cannot be relied upon due to material errors.
Exactus acquires Panacea Life Sciences; Leslie Buttorff becomes CEO
Exactus issues 473.6M common shares + preferred stock to acquire Panacea; Buttorff owns ~61% fully diluted.
On July 21, 2022, Dr. Janice Nerger resigned as a member of the Board of Directors of Panacea Life Sciences Holdings, Inc., effective immediately.
On October 17, 2021, following Exactus, Inc. (the “Company”) compliance with Rule 14f-1 under the Securities Exchange Act of 1934, Dr. Janice Nerger officially became a director of the Company.
John Price, a director (who had not held any officer positions with the Company), previously resigned from as a director of the Company.
Leslie Buttorff was appointed director.
Mr. Wert previously was Executive Chairman but resigned from that role.
On June 30, 2021, Julian Pittam resigned as director of the Company
Max materiality 0.95 · Median 0.60 · Most common event other_material